18F-FACBC Compared With 11C-Choline PET/CT in Patients With Biochemical Relapse After Radical Prostatectomy: A Prospective Study in 28 Patients

Nanni, Cristina; Schiavina, Riccardo; Brunocilla, Eugenio; Borghesi, Marco; Ambrosini, Valentina; Zanoni, Lucia; Gentile, Giorgio; Vagnoni, Valerio; Romagnoli, Daniele; Martorana, Giuseppe; Fanti, Stefano

doi:10.1016/j.clgc.2013.08.002

Cited by 65 publications

(56 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…FACBC is a synthetic cyclic amino acid analogue labelled with fluorine-18 used in investigational PET/ CT for staging and restaging of prostate cancer. The tracer seems to show more metastatic lesions and higher lesion to background uptake compared to PET/CT using carbon-11 or fluorine-18-labelled choline [6]. Administered activity was 3 MBq/kg, with a minimum of 200 MBq.…”

Section: Positron Emission Tomography Scanmentioning

confidence: 99%

Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223

Nome¹,

Hernes

Bogsrud

et al. 2014

Scandinavian Journal of Urology

View full text Add to dashboard Cite

Objective.The aim of this study was to assess treatment-related changes in prostate-specific antigen (PSA), total and bone alkaline phosphatase (total ALP, bone ALP), and changes on conventional bone scans in patients with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases who received six cycles of radium-223 (Ra-223). Materials and methods. Changes in PSA, total ALP and bone ALP ( ‡30% increase or decrease), and changes on bone scans were assessed before and after six monthly cycles of Ra-223 therapy (50 kBq/kg body weight) in 14 patients with mCRPC with bone metastases and four patients on placebo. Results.Post-treatment PSA increased by at least 30% in 11 out of 14 patients and remained stable in three. Total ALP and bone ALP decreased in six and nine patients, respectively. In 10 out of 12 evaluable patients the uptake on post-treatment bone scan was reduced in lesions with high pretreatment uptake, in 11 patients accompanied by the development of new or expanded bone lesions. FACBC position emission tomography/computed tomography scans confirmed the growth of new or expanded bone metastases in two patients. Conclusions.These observations support the notion that Ra-223 kills tumour cells in metastases surrounded by highly proliferating osteoblasts, consistent with the reported survival benefit. The radiation effect in small tumour deposits not surrounded by increased osteoblast activity seems, however, insufficient, thus allowing continuous tumour growth. Long-lasting PSA reductions are the exception rather than the rule during Ra-223 treatment, whereas alkaline phosphatases decrease more frequently. To improve the overall anticancer effect, Ra-223 might be a valuable component of combination treatment.

show abstract

Section: Positron Emission Tomography Scanmentioning

confidence: 99%

Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223

Nome¹,

Hernes

Bogsrud

et al. 2014

Scandinavian Journal of Urology

View full text Add to dashboard Cite

show abstract

“…Detection rates are positively associated with PSA level but are low (,50%) in patients with early BCR (i.e., PSA , 2 ng/mL) (11). Other PET radiopharmaceuticals have been investigated (e.g., 11 C-acetate) or even Food and Drug Administrationapproved (e.g., 18 F-fluciclovine), in part demonstrating superiority over choline derivatives (12)(13)(14)(15).…”

mentioning

confidence: 99%

PSMA Ligands for PET Imaging of Prostate Cancer

et al. 2017

View full text Add to dashboard Cite

“…114 FACBC has been studied primarily in prostate cancer, in which it had higher sensitivity for tumor detection compared with 111 In-capromab pendetide (Prostascint) and 11 C-choline. 115,116 In addition, FACBC has demonstrated increased uptake in papillary renal cell carcinoma, but not in clear cell carcinoma. 117 FACBC is especially notable for the lack of associated radioactivity in the urine, which allows for better evaluation of the genitourinary tract and pelvis.…”

Section: Imaging Protein and Cell Membrane Metabolismmentioning

confidence: 99%

PET/CT imaging in cancer: Current applications and future directions

Farwell

Pryma

Mankoff

2014

Cancer

196

120

View full text Add to dashboard Cite

Positron emission tomography (PET) is a radiotracer imaging method that yields quantitative images of regional in vivo biology and biochemistry. PET, now used in conjunction with computed tomography (CT) in PET/CT devices, has had its greatest impact to date on cancer and is now an important part of oncologic clinical practice and translational cancer research. In this review of current applications and future directions for PET/CT in cancer, the authors first highlight the basic principles of PET followed by a discussion of the biochemistry and current clinical applications of the most commonly used PET imaging agent, 18 F-fluorodeoxyglucose (FDG). Then, emerging methods for PET imaging of other biologic processes relevant to cancer are reviewed, including cellular proliferation, tumor hypoxia, apoptosis, amino acid and cell membrane metabolism, and imaging of tumor receptors and other tumor-specific gene products. The focus of the review is on methods in current clinical practice as well as those that have been translated to patients and are currently in clinical trials. Cancer 2014;120:3433-45.

show abstract

18F-FACBC Compared With 11C-Choline PET/CT in Patients With Biochemical Relapse After Radical Prostatectomy: A Prospective Study in 28 Patients

Cited by 65 publications

References 14 publications

Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223

Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223

PSMA Ligands for PET Imaging of Prostate Cancer

PET/CT imaging in cancer: Current applications and future directions

Contact Info

Product

Resources

About